Besides, Ahn et al.’s hypothesis also put forward the fact that the level of sclerostin molecule decreases to a greater extent in sarcopenic patients suggesting it to act as a therapeutic agent or a potential marker for treating sarcopenia [127]. Here, SOST is linked to sarcopenia.